Entact Bio

Entact Bio is a biotechnology company pioneering the development of a new class of precision medicines called Enhancement-Targeting Chimeric (ENTAC™) molecules. Unlike traditional therapeutics that focus on inhibiting or degrading disease-causing proteins, Entact's approach centers on 'protein enhancement'—restoring or increasing the function of beneficial proteins to treat diseases such as cancer, autoimmune conditions, and rare genetic disorders. The company's proprietary Encompass™ platform integrates biological, chemical, and computational tools to identify disease targets amenable to enhancement. By leveraging deubiquitinases (DUBs), which are enzymes that regulate protein stability and function by removing ubiquitin tags, Entact's ENTAC molecules act as molecular matchmakers to stabilize key proteins, relocate them within the cell, or optimize their activity to restore cellular health.